Cart
sales@molnova.com
Home -
Products -
Endocrinology/Hormones -
Estrogen Receptor/ERR -
5Beta-Pregnane-3Alpha,20alpha-Diol
5Beta-Pregnane-3Alpha,20alpha-Diol
CAS No. 80-92-2
5Beta-Pregnane-3Alpha,20alpha-Diol( —— )
Catalog No. M16025 CAS No. 80-92-2
An inactive metabolite of progesterone by reduction at C5, C3, and C20 position.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 103 | In Stock |
|
| 25MG | 176 | In Stock |
|
| 50MG | 271 | In Stock |
|
| 100MG | 433 | In Stock |
|
| 200MG | 693 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5Beta-Pregnane-3Alpha,20alpha-Diol
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn inactive metabolite of progesterone by reduction at C5, C3, and C20 position.
-
DescriptionAn inactive metabolite of progesterone by reduction at C5, C3, and C20 position. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. It is detectable in URINE after ovulation and is found in great quantities in the pregnancy urine.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorER
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number80-92-2
-
Formula Weight320.52
-
Molecular FormulaC21H36O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESC[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Blackwell LF, et al. Hum Reprod. 2013 Dec;28(12):3306-15.
molnova catalog
related products
-
Estriol
Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast Y cells.
-
SAR439859
SAR439859 is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD).
-
Medicarpin (b)
(+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.
